Evidence map›Paper›PMID 37501353›Full record

ArticleEpilepsia open2023

Epilepsy is an important feature of KBG syndrome associated with poorer developmental outcome.

Nathan Buijsse, Floor E Jansen, Charlotte W Ockeloen, Marjan J A van Kempen, Shimriet Zeidler, Marjolein H Willemsen, Emanuela Scarano, Sonia Monticone, Evelien Zonneveld-Huijssoon, Karen J Low and 10 more

Open access · goldAbstract read
In one paragraph

Article in Epilepsia open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. NovelSultan Qaboos University medical journal · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 5 countries.

Nathan BuijsseDepartment of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0003-4934-8174
Floor E JansenDepartment of Pediatric Neurology, Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Charlotte W OckeloenDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Marjan J A van KempenDepartment of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Shimriet ZeidlerDepartment of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
Marjolein H WillemsenDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Emanuela ScaranoDepartment of Pediatrics, St. Orsola-Malpighi Hospital, Bologna, Italy.
Sonia MonticoneDepartment of Pediatrics, Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy.
Evelien Zonneveld-HuijssoonDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Karen J LowDepartment of Clinical Genetics, University Hospitals Bristol and Weston NHS trust, University of Bristol, Bristol, UK.
Allan BayatDepartment for Genetics and Personalized Medicine, Danish Epilepsy Centre, Dianalund, Denmark.ORCID 0000-0003-4986-8006
Sanjay M SisodiyaDepartment of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology and Chalfont Centre for Epilepsy, Chalfont St Peter, UK.ORCID 0000-0002-1511-5893
Debopam SamantaChild Neurology Section, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0002-5154-8717
Gaetan LescaDepartment of Genetics, University Hospitals of Lyon, Lyon, France.ORCID 0000-0001-7691-9492
Danielle de JongDepartment of Neurology, Academic Center for Epileptology Kempenhaeghe/MUMC+, Heeze, The Netherlands.
Jaqcues C GiltayDepartment of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Nienke E VerbeekDepartment of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Tjitske KleefstraDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Eva H BrilstraDepartment of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Danique R M VlaskampDepartment of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands.
University Medical Center Utrecht · NLRadboud University Nijmegen · NLEpilepsy Society · GBErasmus MC · NLIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITKempenhaeghe · NLUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity Medical Center Groningen · NLUniversity of Arkansas Medical Center · USUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to describe the epilepsy phenotype in a large international cohort of patients with KBG syndrome and to study a possible genotype-phenotype correlation.

methodsWe collected data on patients with ANKRD11 variants by contacting University Medical Centers in the Netherlands, an international network of collaborating clinicians, and study groups who previously published about KBG syndrome. All patients with a likely pathogenic or pathogenic ANKRD11 variant were included in our patient cohort and categorized into an "epilepsy group" or "non-epilepsy group". Additionally, we included previously reported patients with (likely) pathogenic ANKRD11 variants and epilepsy from the literature.

resultsWe included 75 patients with KBG syndrome of whom 26 had epilepsy. Those with epilepsy more often had moderate to severe intellectual disability (42.3% vs 9.1%, RR 4.6 [95% CI 1.7-13.1]). Seizure onset in patients with KBG syndrome occurred at a median age of 4 years (range 12 months - 20 years), and the majority had generalized onset seizures (57.7%) with tonic-clonic seizures being most common (23.1%). The epilepsy type was mostly classified as generalized (42.9%) or combined generalized and focal (42.9%), not fulfilling the criteria of an electroclinical syndrome diagnosis. Half of the epilepsy patients (50.0%) were seizure free on anti-seizure medication (ASM) for at least 1 year at the time of last assessment, but 26.9% of patients had drug-resistant epilepsy (failure of ≥2 ASM). No genotype-phenotype correlation could be identified for the presence of epilepsy or epilepsy characteristics. SIGNIFICANCE: Epilepsy in KBG syndrome most often presents as a generalized or combined focal and generalized type. No distinctive epilepsy syndrome could be identified. Patients with KBG syndrome and epilepsy had a significantly poorer neurodevelopmental outcome compared with those without epilepsy. Clinicians should consider KBG syndrome as a causal etiology of epilepsy and be aware of the poorer neurodevelopmental outcome in individuals with epilepsy.

Indexed as

Abnormalities, MultipleBone Diseases, DevelopmentalEpilepsy, GeneralizedIntellectual DisabilityTooth AbnormalitiesFaciesHumansInfantRepressor ProteinsTranscription FactorsRepressor ProteinsTranscription FactorsANKRD11 genegenotype-phenotype correlationneurodevelopmentseizure

Identifiers

PMID37501353
PMCPMC10690702
OpenAlexW4385330532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.